Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1 Diabetes is under clinical development by Throne Biotechnologies and currently in Phase III for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase III drugs for Type 1 Diabetes (Juvenile Diabetes) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1 Diabetes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1 Diabetes overview
Cell therapy is under development for the treatment of pneumonia caused by coronavirus disease 2019 (COVID-19), alopecia areata and type 1 diabetes. It is administered through intravenous route. The drug candidate comprises of stem cell educator (STE) treated autologous mononuclear cells collected from blood. It acts by targeting cord blood derived stem cell via galectin 9 dependent cell contact mechanism.
Throne Biotechnologies overview
Throne Biotechnologies formerly Tianhe Stem Cell Biotechnologies, is a translational research company that develops stem cell therapies to treat diabetes and autoimmune diseases. Throne Biotechnologies is headquartered in Lisle, Illinois, the US.
For a complete picture of Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1 Diabetes’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
